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SYNOPSIS
Sporadic Creutzfeldt-Jakob disease (sCJD) has not been 
previously reported in patients with clotting disorders treat-
ed with fractionated plasma products. We report 2 cases of 
sCJD identified in the United Kingdom in patients with a his-
tory of extended treatment for clotting disorders; 1 patient 
had hemophilia B and the other von Willebrand disease. 
Both patients had been informed previously that they were 
at increased risk for variant CJD because of past treatment 
with fractionated plasma products sourced in the United 
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SYNOPSIS
Kingdom. However, both cases had clinical and investiga-
tive features suggestive of sCJD. This diagnosis was con-
firmed in both cases on neuropathologic and biochemical 
analysis of the brain. A causal link between the treatment 
with plasma products and the development of sCJD has not 
been established, and the occurrence of these cases may 
simply reflect a chance event in the context of systematic 
surveillance for CJD in large populations.
Human prion diseases are a group of rare and fatal neurodegenerative diseases that include idiopathic 
(sporadic), genetic (inherited), and acquired (infectious) 
disorders (1). All are associated with the accumulation of 
an abnormal isoform of the prion protein (PrPSc) in the cen-
tral nervous system (1). The most common human prion 
disease is the sporadic form of Creutzfeldt-Jakob disease 
(sCJD), which occurs worldwide with a relatively uniform 
incidence of 1–2 cases per million population per year, 
a peak incidence in the 7th decade of life, and a median 
duration of illness of 4 months. The relatively consistent 
mortality rates associated with sCJD, the overall random 
spatial and temporal distribution of cases, and the absence 
of any confirmed environmental risk factor have led to 
the hypothesis that sCJD occurs because of the spontane-
ous generation of PrPSc in the brain (1). In contrast, variant 
Creutzfeldt-Jakob disease (vCJD) is an acquired disorder 
that is most likely caused by the consumption of meat or 
meat products contaminated with the bovine spongiform 
encephalopathy agent. The median age at death in vCJD is 
30 years, with a median duration of illness of 14 months. 
Most cases of vCJD have occurred in the United Kingdom, 
which has had the largest epizootic of bovine spongiform 
encephalopathy in the world. Of the 178 UK vCJD cases, 
3 have been identified as cases of secondary transmission 
caused by the transfusion of nonleukodepleted red blood 
cell components from vCJD-infected blood donors.
Lookback studies have shown no evidence of trans-
mission through blood transfusion in sCJD (2,3), despite 
the identification of PrPSc in some peripheral tissues (4) 
and experimental evidence, which demonstrated infectiv-
ity in blood (5) by using intracerebral inoculation of highly 
sensitive transgenic mice. The absence of clinical cases 
causally linked to past treatment with fractionated plasma 
products has been used as evidence of the safety of these 
products in relation to sCJD (6). These products are gen-
erally manufactured from the pooled plasma from several 
thousand donors; production using UK plasma was discon-
tinued in 1999.
We describe 2 cases of sCJD in patients who had 
previously received treatment with UK plasma–sourced 
plasma products; both patients had been informed that they 
were at increased risk for vCJD because of that treatment. 
The clinical features and investigations in these cases were 
typical of sCJD; the neuropathologic diagnosis in both cas-
es was sCJD (subtype MM1). 
The Investigation
The UK National CJD Research and Surveillance Unit has 
been carrying out systematic epidemiologic study of CJD 
since 1990. The methodology of this study has been pub-
lished previously (7). In brief, patients with suspected CJD 
are referred by clinicians and visited by a research registrar, 
who obtains details of the clinical history and investiga-
tions, information on a range of possible risk factors, and 
past medical history. The Transfusion Medicine Epidemi-
ology Review study investigates potential links between 
donors and recipients of labile blood components and, in 
cases of sCJD, investigates patients who have a history of 
blood donation or having received a blood transfusion.
Coordinated surveillance of CJD has been undertaken 
in the European Union since 1993 (8). National surveil-
lance programs for CJD also are in place in several oth-
er countries, including Australia, Canada, Japan, and the 
United States.
Case 1
In 2014, a 64-year-old woman suffered a rapidly progres-
sive dementia with deterioration in driving skills and bal-
ance disturbance, then limb coordination deficits with 
handwriting impairment. In the second month, her gait de-
teriorated, becoming shuffling and unsteady, she struggled 
to dress herself, and she had onset of daytime hypersomno-
lence. She became distractible, had visual misperceptions, 
emotional lability, and spatial memory problems. She was 
hospitalized at the beginning of the third month of her ill-
ness and had onset of cortical blindness, myoclonus, and 
akinetic mutism. She experienced rapid decline and died 
after a total illness duration of 3 months.
An electroencephalogram performed during the final 
stages of illness showed background slowing and runs of 
periodic complexes, and a magnetic resonance imaging 
(MRI) brain scan showed high signal in the caudate heads 
with posterior cortical ribboning. A cerebral spinal fluid 
(CSF) 14–3–3 assay and real-time quaking-induced con-
version test for PrPSc both were positive. Prion protein gene 
(PRNP) sequencing showed no mutations with methionine 
homozygosity at codon 129.
Postmortem examination of the brain showed wide-
spread spongiform encephalopathy of predominantly mi-
crovacuolar type. Immunocytochemistry for prion protein 
gave a widespread positive reaction in a granular/synap-
tic pattern (Figure). No plaques or plaque-like structures 
were identified. Results of immunocytochemistry for dis-
ease-associated prion protein were negative in peripheral 
nerve, liver, lymph node, appendix, and spleen. Western 
blot analysis of frontal cortex and cerebellum confirmed 
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the presence of protease-resistant prion protein with a type 
1A isoform.
The patient had been diagnosed with von Willebrand 
disease in childhood. Her early therapies include numer-
ous transfusions of red blood cells and platelets; in more 
recent years, she received plasma-derived and recombinant 
factor VIII and additional blood component transfusions at 
times of hemorrhage. Factor VIII was administered on 4 
occasions in the 1990s and during 2000–2004 and von Wil-
lebrand factor/factor VIII (Haemate-P) during 2001–2013. 
Because of her history of exposure to UK-sourced plasma 
products, for public health purposes she had been informed 
that she was at risk for vCJD, although she was not known 
to have been exposed to factor VIII derived from a batch 
including a vCJD donation. She had no history of potential 
iatrogenic exposure to CJD and no family history of CJD.
Donors for all blood or platelet transfusions since 2001 
have been identified. Of the 107 donors, 106 are still alive, 
with a median age of 55 years (range 27–80 years). (Table 1). 
One donor of leukodepleted platelets, which were transfused 
12 years before clinical onset in the recipient, died in 2013 
at 76 years of age, and the diagnoses on the death certificate 
were vascular dementia and bladder cancer. Identification of 
donors for transfusions before 2001 has not been possible.
Case 2
In 2014, a 64-year-old woman reported day/night reversal 
of sleep patterns and, 3 months later, excessive tearfulness, 
for which she was started on antidepressants. She then had 
onset of writing problems, followed during the next few 
days by increasing language problems that led to expres-
sive dysphasia. She deteriorated rapidly thereafter, requir-
ing assistance with her activities of daily living and having 
coordination and memory problems, jerking movements 
suggestive of myoclonus, and itching in both arms. She 
was admitted to the hospital and experienced a probable 
focal seizure with secondary generalization. She had onset 
of a homonymous hemianopia and limb rigidity and then 
became bedbound and mute, dying 7 months after the onset 
of symptoms.
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Figure. Results of 
neuropathologic examinations 
of the brains of the 2 patients 
with sporadic Creutzfeldt-Jakob 
disease, United Kingdom, 2014. 
A) Microvacuolar spongiform 
change in the frontal cortex 
(case 1). Hematoxylin and eosin 
stain; original magnification 
×400. B) Fine granular/
synaptic accumulation of 
abnormal prion protein in the 
cerebral cortex (case 1). 12F10 
antiprion protein antibody; 
original magnification ×400. 
C) Microvacuolar spongiform 
change with neuronal loss and 
gliosis in the frontal cortex (case 
2). Hematoxylin and eosin stain; 
original magnification ×400. 
D) Focally intense granular/
synaptic accumulation of 
abnormal prion protein in the 
cerebral cortex (case 2). 12F10 





Table 1. Selected characteristics of blood donors to the patient with sporadic Creutzfeldt-Jakob disease described in case 1, United 
Kingdom, 2014* 
Interval from 
transfusion to onset, y Component No. donors No. donors alive No. donors dead 
3 RBC LD 4 4 0 
6 RBC LD 6 6 0 
7 RBC LD 19 19 0 
9 RBC LD 3 3 0 
10 RBC LD 4 4 0 
12 Whole blood LD; RBC LD; platelets LD 2; 27; 42 2; 27; 41 0; 0; 1 
*LD, leukodepleted; RBC, red blood cells. Median age of donors, 56 years (range 27–80 years). 
 
SYNOPSIS
An electroencephalogram performed during the final 
stages of illness showed widespread slowing, more evident 
on the left. An MRI brain scan showed left-sided caudate 
head and anterior putaminal high signal. Diffusion weight-
ed imaging showed areas of cortical high signal. Results of 
a CSF 14–3–3 assay and real-time quaking-induced con-
version tests were positive. Consent for full sequencing of 
the PRNP was not obtained; methionine homozygosity at 
codon 129 was identified.
Postmortem neuropathologic examination of the brain 
showed a widespread spongiform encephalopathy with mi-
crovacuolar spongiform change, neuronal loss, and gliosis. 
Immunostaining for prion protein showed widespread posi-
tivity with a granular/synaptic pattern (Figure). No amyloid 
plaques were identified. Western blot analysis confirmed 
the presence of protease resistant prion protein with a type 
1A isoform. There was no evidence of abnormal prion pro-
tein accumulation in spleen and appendix either on immu-
nocytochemistry or high sensitivity Western blot analysis.
The patient was known to have hemophilia B since 
1964 and had received plasma-derived and recombinant 
factor IX during 1984–2012. For public health purposes, 
she had been informed that she was at risk for vCJD and in 
1991 had received factor IX derived from a pool containing 
plasma from a donor who subsequently had vCJD. She had 
no history of potential iatrogenic exposure to CJD and no 
family history of CJD.
In 1985, the patient received 6 units of fresh frozen 
plasma (FFP). Tracing of donors has not been possible. 
Discussion
This report describes 2 cases of sCJD in patients with a his-
tory of treatment with UK-sourced plasma products, 1 with 
a history of hemophilia B and 1 with von Willebrand’s dis-
ease. To our knowledge, no previous case of sCJD in a per-
son with a history of extended exposure to plasma products 
has been reported. It is clearly of concern that there have 
been 2 such cases in a relatively short period in the UK, 
where many plasma product recipients have been informed 
that they are at increased risk for vCJD. However, a causal 
link between the treatment with plasma products and the 
onset of sCJD has not been established, and the occurrence 
of these cases may simply reflect a chance event in the con-
text of systematic surveillance of CJD in large populations.
Both patients had been informed that they were at in-
creased risk for vCJD, and considering the evidence for the 
type of CJD in the 2 cases is important. Both patients had 
a clinical phenotype suggestive of sCJD, including a short 
duration of illness, typical early symptoms, a suggestive 
MRI scan, and, in 1 patient, a typical EEG. Notably, both 
patients had a positive real-time quaking-induced conver-
sion test result for PrPSc in CSF; previously this test had not 
been positive in any case of vCJD evaluated in our labora-
tory (Table 2) (9). However, neuropathological examina-
tion was critical; it showed appearances typical of sCJD in 
both patients and no evidence of peripheral pathogenesis 
on immunostaining of lymphoreticular tissues, a feature 
that is observed in all tested specimens of vCJD patients 
to date (10). Furthermore, both patients had a type 1A iso-
form PrPSc on Western blot consistent with a diagnosis of 
sCJD subtype MM1 (11). Neither patient had a history of 
potential iatrogenic exposure or a family history of CJD, 
and for the case for which sequencing of the PRNP was 
performed, no mutations were detected. In both cases, an 
MM genotype occurred at codon 129 of PRNP, which does 
not distinguish between sCJD and vCJD. Laboratory trans-
mission studies to provide evidence of agent strain in the 
cases have not been possible.
One patient had received multiple transfusions of blood 
components over an extended period, and the other had re-
ceived 6 units of FFP 19 years before clinical onset, raising 
the possibility that these cases could have resulted from sec-
ondary transmission through blood components. In the case 
of the patient with von Willebrand disease, 107 donors have 
been traced, and none appear in the register of cases of CJD 
kept at the National CJD Research and Surveillance Unit. 
However, it has not been possible to obtain information 
on blood transfusions for this patient before 2001 nor on 
the FFP transfusions for the patient with hemophilia B. 
Lookback studies in the United States and United Kingdom 
have provided no evidence of transfusion-transmission of 
sCJD (2,3), and although 1 study suggested an increase in 
risk after a lag period of 10 years (12), this finding was not 
confirmed in another study (13). The balance of evidence 




Table 2. Selected characteristics and clinical features of the 2 patients with sCJD described in cases 1 and 2, United Kingdom, 2014* 
Characteristic/clinical feature  Case 1 Case 2 
Patient age, y/sex 64/F 64/F 
Symptoms/signs Ataxia, cognitive impairment, visual 
impairment, myoclonus 
Somnolence/depression, dysphasia, 
cognitive impairment, myoclonus/ataxia 
Magnetic resonance imaging + + 
Electroencephalogram  + Slow activity 
Cerebrospinal fluid 14–3–3 assay + + 
RT-QuIC  + + 
Genotype MM MM 
Diagnosis Definite sCJD Definite sCJD 
Duration 3 mo 7 mo 
*RT-QuIC, real-time quaking-induced conversion; sCJD, sporadic Creutzfeldt-Jakob disease. 
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indicates that, if sCJD is transmitted by blood transfusion, 
it must be a rare event, if it happens at all, and transfusion 
transmission is probably not the explanation for the 2 cases 
we describe.
Systematic surveillance for CJD, including a coordi-
nated study in Europe (14), has been carried out in many 
countries over the past 25 years and is continuing. Many of 
these studies obtain information on potential risk factors, 
including details of past medical history. To date, no case 
of sCJD has been reported in a person who has received 
treatment for a clotting disorder. In fact, the absence of such 
a case has been used to argue against the possibility that 
plasma-derived products pose a risk for sCJD transmission 
(6). CJD surveillance centers are aware of the relevance of 
this issue, and sCJD patients with a history of treatment 
with plasma products probably would have been identified 
and reported if they occurred. Although it is surprising that 
2 cases of sCJD have been identified among a population of 
4,000–5,000 patients in the UK who have been treated for 
clotting disorders with fractionated plasma products, the 
total population under surveillance for CJD in Europe and 
internationally exceeds 500 million. Assuming an annual 
incidence rate of sCJD of 1.5–2.0 per million population 
(15), the occurrence of 2 cases of sCJD in this total popula-
tion may not imply a causal link between the treatment and 
the occurrence of the disease. The 2 cases were identified 
over a period of months, and no further cases have been 
found since 2014; however, continuing to search for such 
cases through CJD surveillance programs is essential.
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